Microsaic Systems partner with Axcend Corp

Microsaic Systems plc (LON:MSYS), the developer of point of need mass spectrometry instruments, today announced that it has signed a global integration and joint sales and marketing heads of terms with Axcend Corp to integrate the compact Microsaic 4500 MiD® MS with the portable Axcend Focus LC®, and to commercialise the combined system globally using both companies’ direct sales and selected distribution channels.  Microsaic has a direct sales presence in the UK and certain European markets, while Axcend has a direct presence in North America; both partners have extensive and growing networks of international distribution partners.

The Microsaic 4500 MiD® is a robust and compact MS detector with an integrated computer and vacuum pump, whose small footprint and ease of use make it deployable anywhere within a laboratory or processing facility.  The Axcend Focus LC® is a very small footprint, high-performance liquid chromatography system (“HPLC”).

Both LC and MS are standard analyses that are widely adopted and the ability to offer both in an easy-to-use compact LC/MS system is expected to deliver users with significant efficiency benefits without compromising on performance, speed or reliability.

Liquid chromatography (“LC”) is a well-established method of sample separation. LC very commonly uses MS as a detection method in a wide range of markets, such as chemicals, pharmaceuticals and environmental analysis. Typically, due in part to the size and complexity of traditional LC and MS systems, such analyses are performed in a centralised laboratory. The combination of Axcend and Microsaic’s small footprint technologies supports timely testing in the location where samples are taken, as well as in centralised laboratories.  In addition, the combined LC/MS system utilises substantially less solvents than the traditonal LC and MS systems, which can, therefore, result in lower running costs and solvent disposal.

The analytical HPLC-MS market is a $5 billion market today, according to Top Down Analytics, 2019 Outlook; Analytical Instruments Industry. 

Glen Mella, CEO, Axcend commented: “We have an award-winning, lightweight and powerful HPLC that is easy-to-use and cost-competitive, especially on an operational basis. Yet many scientists need the added benefit of an LC/MS system to produce greater analytical insights. We are confident that Microsaic will be an excellent partner for delivering compelling solutions to our customers.”

Glenn Tracey, CEO, Microsaic added: “We are particularly excited by this partnership, which combines two highly differentiated compact products into a very powerful LC/MS system. In addition to the benefits for customers, this collaboration also leverages our shared resources of marketing, direct sales and distribution channels globally. As far as we are aware there is no other LC/MS combination today which provides such a powerful offering in such a small footprint.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn

    More articles like this

    Microsaic Systems plc

    VIDEO: Microsaic Systems Investor Presentation 2019

    Microsaic Systems (LON:MSYS) Investor Presentation by Glenn Tracey. Microsaic Systems plc is a high technology company developing chip-based, bench-top and point-of-analysis mass spectrometry (“MS”) instruments that are designed to improve the efficiency of pharmaceutical R&D and

    Microsaic Systems plc

    Microsaic Systems plc Introduce New Protein Identification Product

    Glenn Tracey, CEO of Microsaic, commented, “Bringing the power of the centralised laboratory to in-situ bioprocessing line measurements, the Microsaic MiD® ProteinID reduces key bioprocessing analyses from days to minutes. This means that operators can monitor

    Microsaic Systems plc

    Advances in Analytics for Bioprocessing

    Richard Moseley, Chief Technologist at Microsaic talks to Biopharma International about process analytical technology (PAT) for monitoring and controlling biopharma production processes. When FDA’s process analytical technology (PAT) initiative was first unveiled, the aim was to

    Microsaic Systems plc

    The need for the miniaturisation of mass spectroscopy

    Microsaic Systems’ Chief Technologist, Richard Moseley, explains the need for miniaturised mass spectrometry, and where the technology can take some key industries such as pharma and biopharma. Arguably the work-horse of most analytical laboratories, mass spectrometry

    Microsaic Systems plc

    Encouraging efficiency

    Encouraging efficiency in pharmaceutical discovery and manufacturing, Microsaic’s Chief Technologist Dr. Richard Moseley discusses chip-based technologies and miniaturisation of mass spectrometry. The current challenges faced by the pharmaceutical industry are nothing new – high costs and

    Microsaic Systems plc

    Innovations in measurement, analysis and testing

    Richard Moseley, Chief Technologist at Microsaic Sytems PLC explains why accurate, timely and efficient measurement techniques are key to optimising production processes in pharmaceutical manufacturing and providing regulators with assurance on product quality. Specialist analytical chemists typically

    MySale Group Plc

    UK retail sees record online spending in 2018

    The latest UK retail report from the Office for National Statistics (ONS), revealed that in the three months to August, the quantity bought increased by 2 percent when compared with the previous three months, with continued

    Microsaic Systems plc

    INTERVIEW: Microsaic Systems 96% Increase in revenues

    Microsaic Systems Plc (LON:MSYS) CEO Glenn Tracey talks to DirectorsTalk about its unaudited interim results for the six months ended 30 June 2018. With a 96% increase in revenues and good operation progress Glenn provides us